Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction

Area of Science:

• Ophthalmology
• Immunology
• Endocrinology

Background:

• Diabetic retinopathy (DR) is a microvascular complication linked to inflammation.
• The NLRP3 inflammasome pathway is implicated in inflammatory processes.
• The therapeutic potential of MCC950, an NLRP3 inhibitor, in DR remains unexplored.

Purpose of the Study:

• To evaluate the anti-inflammatory effects of MCC950 on high-glucose-induced human retinal endothelial cells (HRECs).
• To investigate the underlying mechanism of MCC950's action in the context of DR.

Main Methods:

• Analysis of NLRP3 inflammasome components (NLRP3, caspase 1, IL-1β) in DR patient tissues.
• Assessment of MCC950's effects on high-glucose-stimulated HRECs, including apoptosis and inflammasome activation.
• Investigation of NEK7's role and its interaction with NLRP3 using siRNA and co-immunoprecipitation.

Main Results:

• Elevated NLRP3, caspase 1, and IL-1β expression observed in DR tissues, with co-localization in HRECs.
• MCC950 treatment rescued high-glucose-induced HREC apoptosis and NLRP3 inflammasome activation.
• MCC950 inhibited Nek7 and NLRP3 interaction, suggesting a mechanism involving the Nek7-NLRP3 pathway.

Conclusions:

• MCC950 demonstrates anti-inflammatory and protective effects against high-glucose-induced HREC dysfunction.
• The findings suggest MCC950 may exert its protective effects by downregulating the Nek7-NLRP3 pathway.
• MCC950 represents a potential therapeutic agent for diabetic retinopathy treatment.